Janssen promises full focus on Darzalex after defeating Genmab in court

Although a ruling in Janssens favor comes as a slap in the face to its partner Genmab, the former has promised to continue to support bestseller drug Darzalex.

Photo: Piroschka Van De Wouw/Reuters/Ritzau Scanpix

While Genmab remains tight-lipped about its defeat in court over a royalties dispute with partner Janssen, the latter has been a little more outspoken about the expected consequences of the ruling.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs